Drug Profile
MK 5478
Alternative Names: MK5478Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Hypertension
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Hypertension in Belgium (PO, Capsule)
- 12 Jan 2011 Merck completes a phase I trial in Hypertension in Belgium
- 16 Dec 2009 Phase-I clinical trials in Hypertension in Belgium (PO)